Find and Pitch Jounalists, Get Your Story Covered

Tags: hardware robotics startups funding industrial robotics

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 6 days ago STAT+: Up and down the ladder: The latest comings and goings - 9 days ago STAT+: Up and down the ladder: The latest comings and goings - 16 days ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 16 days ago STAT+: Up and down the ladder: The latest comings and goings - 23 days ago STAT+: Up and down the ladder: The latest comings and goings - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: U.K. trade group scolds Novo, Novartis, Pfizer, and Otsuka for violating industry codes - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago STAT+: Up and down the ladder: The latest comings and goings - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 11 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 11 months ago STAT+: Up and down the ladder: The latest comings and goings - 11 months ago STAT+: Up and down the ladder: The latest comings and goings - 12 months ago STAT+: Up and down the ladder: The latest comings and goings - 12 months ago STAT+: Up and down the ladder: The latest comings and goings - about 1 year ago STAT+: Up and down the ladder: The latest comings and goings - about 1 year ago STAT+: Up and Down the Ladder: The latest comings and goings - about 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - about 1 year ago STAT+: Up and down the ladder: The latest comings and goings - about 1 year ago STAT+: Up and down the ladder: The latest comings and goings - about 1 year ago STAT+: Up and down the ladder: The latest comings and goings - about 1 year ago
2	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Pharma takes aim at a wily foe — the Epstein-Barr virus - 13 days ago 2024 PharmaVoice 100s: Trailblazers - about 1 month ago What 3 layoff stories reveal about pharma’s troubles - 2 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 5 months ago Where competition is heating up in pharma - 6 months ago The biggest questions hanging over pharma in 2024 - 10 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - 10 months ago 3 standout digital innovations in pharma this year - 12 months ago PharmaVoice 100s: Entrepreneurs - about 1 year ago PharmaVoice 100s: Clinical trial gurus - about 1 year ago
3	Pharmacy Times Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Unmasking Health Care Fraud: RICO Is Increasingly Being Used in the Pharmaceutical Industry - about 1 month ago
4	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	M&A is ready to explode, and that’s good news for pharma layoffs - 3 months ago As the GLP-1 market booms, other healthcare companies are cashing in - 4 months ago Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work? - 6 months ago As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene - 8 months ago
5	PT Staff Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	June 2024 Products Column - 5 months ago
6	Beth Mole Ars Technica Senior Health Reporter @ArsTechnica. microbiologyinfectious diseasespublic health	Big Pharma spends billions more on executives and stockholders than on R&D - 9 months ago
7	Mike Hennessy Jr, President and CEO Pharmacy Times Pro middleweight boxer. UK/Ireland. BoxingSports	Pharmacists Are Vital to Heart Health - 9 months ago
8	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	2024 - 10 months ago
9	Nicholas Florko STAT News Reports on US health business. Washington, DC healthcarepolicy	STAT+: Medical marijuana companies are using pharma’s sales tactics with little of the same scrutiny - 11 months ago
10	Kelly Bilodeau Pharma Voice Mom, wife, freelance writer. writing	What are pharma’s next blockbusters? - 11 months ago Oncology drugmakers seek the sweet spot between efficacy and tolerability - 11 months ago From the rainforest to Wall Street — Jaguar Health’s big play for revitalization - about 1 year ago

Journalists covering pharmaceutical industry